Enhance your practice with CME and tools that focus on diseases and conditions impacting the female patient.
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Shared Goals, Shared Gains: Align With Patient Preferences
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Turning Flares Into Function: Flag Uncontrolled Disease
Minimal By Design: Define MSE Endpoints
When to Begin FcRn: Initiation Criteria, Key Evidence
Target Locked in gMG: Why T2T Matters
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Escalate With Intention: Stepwise, Target-Anchored Moves
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Precision Starts Before Birth: Reimagining Fetal Care Through FcRn Immune Modulation
Kenneth J. Moise Jr., MD
Kara B. Markham, MD
Not Just a Headache: Migraine Across Women’s Lifespan
Jelena Pavlović, MD, PhD
Amaal J. Starling, MD, FAHS, FAAN
ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive Years
Linda Bradley, MD
Obianuju Sandra Madueke-Laveaux, MD, MPH
Lauren R. Kornegay
Women’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages
Alison Kole, MD, MPH, FACCP
Ghada Bourjeily, MD, FCCP
Rashmi Nisha Aurora, MD
Audrey Wells, MD
The Alloimmune Disorders of Pregnancy
Karin J. Blakemore, MD
Emilie L. Vander Haar
The IgG Clock: Redose Using IgG Kinetics
The 2-Point Signal: Apply ≥2-Point Rule
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Diagnosing and Treating IBS: It Begins With One Simple Question
Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE
Kimberly D. Orleck, PA-C
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Sawsan As-Sanie, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Lee P. Shulman, MD, FACMG, FACOG
Samantha Denäe
Pre- and Postoperative Use of GnRH Antagonists
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): Overcoming Diagnostic and Therapeutic Challenges
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
The Integral Role of GnRH Antagonists in the Management of Endometriosis
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
Why Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
Roberto Romero, MD, DMedSci
Alloimmune Neutropenia of the Fetus and Newborn
Masja de Haas, MD, PhD
Alloimmune Thrombocytopenia in the Fetus and Newborn
James B. Bussel, MD
Loading...
We're glad to see you're enjoying Omnia Education… but how about a more personalized experience?
Press cancel to remain on Omnia Education. Press the link below or the continue button to keep going.